CoronaVac
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
CoronaVac is a potential COVID-19 vaccine candidate developed by Sinovac.[1] It is currently undergoing Phase III clinical research.
Testing[edit]
In a Phase II clinical trial was completed in July 2020, CoronaVac showed immunogenicity of a low 3μg dose led to a 92.4% seroconversion.[2]
Latin America Phase III Trials
In late July 2020, Sinovac began conducting Phase III vaccine trials to evaluate efficacy and safety of its vaccine in Brazil with Butantan Institute on 9,000 volunteers, all health professionals, in six Brazilian states.[3] In exchange, Brazil was promised 120 million doses of the vaccine if it was found to be effective.[4] Also in early August, Chile began supporting a phase III trial headed by Pontifical Catholic University of Chile with Sinovac, which was expected to include 3,000 volunteers between the age of 18 and 65.[5]
Asia Phase III Trials
In August 2020, Sinovac began conducting additional Phase III vaccine trials in Bangladesh with the International Centre for Diarrhoeal Disease Research involving 4,200 volunteers and in Indonesia with Bio Farma in Bandung involving 1,620 volunteers.[6][7] The Indonesian trial is being conducted at Padjadjaran University's Faculty of Medicine and has been welcomed by Indonesia's president Jokowi and several high goverment officials have signed up.[1] In late August 2020, Indonesian Foreign Minister Retno Marsudi said a purchased agreement was signed with Sinovac for 50 million doses of the vaccine from November to March.[8] In early September, the Philippines Department of Health announced five hospitals as possible sites for Phase III trials in the Philippines.[9]
In late August, CoronaVac was approved for emergency use as part of a program in China to vaccinate high-risk groups such as medical staff.[10]
Production[edit]
A 20,000 square meter production plant has been built for manufacturing the Coronavac vaccine. Construction of the plant started in March, and the facility will eventually produce 300 million doses a year, if the vaccine is successful and approved.[4]
References[edit]
- ^ a b "Indonesia Starts CoronaVac Phase 3 Clinical Trials". Jakarta Globe. Retrieved 2020-08-26.
- ^ Zhang, Yan-Jun; Zeng, Gang; Pan, Hong-Xing; Li, Chang-Gui; Kan, Biao; Hu, Ya-Ling; Mao, Hai-Yan; Xin, Qian-Qian; Chu, Kai; Han, Wei-Xiao; Chen, Zhen (2020-08-10). "Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial". medRxiv: 2020.07.31.20161216. doi:10.1101/2020.07.31.20161216.
- ^ Savarese, Mauricio (21 July 2020). "New coronavirus vaccine trials start in Brazil". Associated Press. Retrieved 15 August 2020.
- ^ a b CNN, David Culver and Nectar Gan. "Inside the company at the forefront of China's push to develop a coronavirus vaccine". CNN. Retrieved 2020-08-27.
- ^ "Chile initiates clinical study for COVID-19 vaccine". Government of Chile. 4 August 2020. Retrieved 2020-08-28.
- ^ Paul, Ruma (27 August 2020). "Bangladesh approves late-stage trial of China's Sinovac COVID-19 vaccine candidate". Reuters.
- ^ "Indonesia eyes production of 250 million doses a year of coronavirus vaccine". Reuters. 4 August 2020. Retrieved 15 August 2020.
- ^ "Indonesia books 50 million coronavirus vaccine doses from Sinovac". Reuters. 2020-08-21. Retrieved 2020-08-21.
- ^ "DOH eyes 5 hospitals for Sinovac vaccine Phase 3 clinical trial". People's Television Network. Retrieved 31 August 2020.
- ^ "Sinovac's coronavirus vaccine candidate approved for emergency use in China - source". Reuters. 2020-08-29. Retrieved 2020-08-30.
 | This vaccine article is a stub. You can help Wikipedia by expanding it. |